ALK and non-small cell lung carcinoma: SCLC transdifferentiation can also manifest in anaplastic lymphoma kinase (ALK)-translocated NSCLC following ALK-TKI therapy [17], immune-checkpoint inhibitor treatment [18], and even spontaneously without intervention [19].